



PRESS RELEASE • PRESS RELEASE • PRESS RELEASE

## NEOVACS GRANTED 1.2 MILLION EURO IN RESEARCH TAX CREDIT

**Paris, June 26, 2013** – NEOVACS (Alternext Paris: ALNEV), a leader in therapeutic vaccines for the treatment of autoimmune diseases announced today that it has received 1.2 million Euros in research tax credit for R&D expenses incurred in 2012.

*“Investment is key for innovative companies like NEOVACS. R&D makes up for 75% of our expenses. The funds that we receive today strengthen our financial position, and show real public support for research and innovation in auto-immune diseases.”* commented Guy Charles Fanneau de La Horie, CEO of NEOVACS.

The funds received today will be dedicated to future clinical development of the company.

### About NEOVACS

NEOVACS is a biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. The company’s proprietary technology covered by five patent families that run until at least 2023 has generated to date 2 product candidates in 3 severe diseases: TNF-Kinoid for Rheumatoid Arthritis and Crohn’s Disease and IFN $\alpha$ -Kinoid for Lupus. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.

For more information on Neovacs, visit [www.neovacs.fr](http://www.neovacs.fr)

### Contacts

#### Presse – ALIZE RP

Caroline Carmagnol  
+33 (0)1 42 68 86 43  
[caroline@alizerp.com](mailto:caroline@alizerp.com)

#### NEOVACS

Nathalie Trépo  
+33 0 1 53 10 93 00  
[ntrepo@neovacs.com](mailto:ntrepo@neovacs.com)

#### Investors / NewCap

Valentine Brouchet  
+ 33 (0) 1 44 71 94 93  
[neovacs@newcap.fr](mailto:neovacs@newcap.fr)